Eli Lilly Japan — Revenue increased by 17.9% to $654.10M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 17.0%, from $559.20M to $654.10M. Over 4 years (FY 2021 to FY 2025), Japan — Revenue shows relatively stable performance with a -2.6% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates successful product launches, strong market demand, or favorable pricing dynamics in Japan, while a decrease may signal increased competition, pricing pressure from government health authorities, or supply chain constraints.
This metric represents the total net sales generated from pharmaceutical products sold within the Japanese geographic ma...
Comparable to regional revenue segments reported by other multinational pharmaceutical companies, often evaluated against local market growth rates and currency fluctuations.
lly_segment_jp_revenues| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $665.40M | $595.00M | $534.80M | $410.20M | $454.40M | $487.70M | $395.00M | $387.20M | $455.60M | $390.80M | $439.00M | $363.90M | $462.70M | $429.10M | $559.20M | $402.20M | $521.00M | $554.70M | $654.10M |
| QoQ Change | — | -10.6% | -10.1% | -23.3% | +10.8% | +7.3% | -19.0% | -2.0% | +17.7% | -14.2% | +12.3% | -17.1% | +27.2% | -7.3% | +30.3% | -28.1% | +29.5% | +6.5% | +17.9% |
| YoY Change | — | — | — | — | -31.7% | -18.0% | -26.1% | -5.6% | +0.3% | -19.9% | +11.1% | -6.0% | +1.6% | +9.8% | +27.4% | +10.5% | +12.6% | +29.3% | +17.0% |
We use cookies for analytics. See our Privacy and Cookie Policy.